ERBB2 and breast carcinoma: In this cohort study of older Medicare beneficiaries diagnosed with ERBB2-positive breast cancer between 2010 and 2019, we observed a narrowing of racial and ethnic disparities in the receipt of ERBB2-targeted therapies over time.